Literature DB >> 19396447

[Topical inhibition of angiogenesis at the cornea. Safety and efficacy].

B Regenfuss1, F Bock, B Bachmann, Y König, D Hos, A Parthasarathy, C Cursiefen.   

Abstract

BACKGROUND: The efficacy and safety of novel topical inhibitors of corneal neovascularisation will be discussed.
METHODS: A literature review after a PUBMED search and own clinical and experimental results are presented.
RESULTS: The off-label use of Avastin eye drops and GS101 eye drops against insulin receptor substrate (IRS)-1, which have been tested in phase II trial, both seem to be relatively efficient and safe ways to inhibit progressive corneal neovascularisation. Other VEGF antagonists, such as ranibizumab and pegaptanib eye drops also inhibit corneal neovascularisation.
CONCLUSIONS: Avastin and GS101 eye drops are the first specific angiogenesis inhibitors for topical inhibition of corneal angiogenesis available for clinical use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396447     DOI: 10.1007/s00347-009-1934-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  27 in total

Review 1.  Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.

Authors:  Claus Cursiefen; Lu Chen; M Reza Dana; J Wayne Streilein
Journal:  Cornea       Date:  2003-04       Impact factor: 2.651

Review 2.  Immune privilege and angiogenic privilege of the cornea.

Authors:  Claus Cursiefen
Journal:  Chem Immunol Allergy       Date:  2007

Review 3.  Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman.

Authors:  Birgit Regenfuss; Felix Bock; Anand Parthasarathy; Claus Cursiefen
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

Review 4.  [Inhibition of angiogenesis in the anterior chamber of the eye].

Authors:  F Bock; Y König; T Dietrich; P Zimmermann; M Baier; C Cursiefen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

5.  Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.

Authors:  C Cursiefen; H Wenkel; P Martus; A Langenbucher; N X Nguyen; B Seitz; M Küchle; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

6.  Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade.

Authors:  Tina Dietrich; Jasmine Onderka; Felix Bock; Friedrich E Kruse; Dörte Vossmeyer; Roland Stragies; Grit Zahn; Claus Cursiefen
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

7.  Safety profile of bevacizumab on cultured human corneal cells.

Authors:  Efdal Yoeruek; Martin S Spitzer; Olcay Tatar; Sabine Aisenbrey; Karl U Bartz-Schmidt; Peter Szurman
Journal:  Cornea       Date:  2007-09       Impact factor: 2.651

8.  The effect of topical bevacizumab on corneal neovascularization.

Authors:  Sang Woo Kim; Byung Jin Ha; Eung Kweon Kim; Hungwon Tchah; Tae-im Kim
Journal:  Ophthalmology       Date:  2008-04-24       Impact factor: 12.079

9.  Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty.

Authors:  Claus Cursiefen; Peter Martus; Nhung X Nguyen; Achim Langenbucher; Berthold Seitz; Michael Küchle
Journal:  Cornea       Date:  2002-10       Impact factor: 2.651

10.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Authors:  Felix Bock; Yanyan König; Friedrich Kruse; Martin Baier; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-13       Impact factor: 3.117

View more
  8 in total

1.  [Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction].

Authors:  B Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

3.  [Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva].

Authors:  C Cursiefen
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 4.  Ocular Barriers and Their Influence on Gene Therapy Products Delivery.

Authors:  Bastien Leclercq; Dan Mejlachowicz; Francine Behar-Cohen
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

Review 5.  [Ophthalmological complications in Sjögren's syndrome].

Authors:  C Jacobi; C Cursiefen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

6.  Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Authors:  Omar M Kirat; Hassan A Al-Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-05-27

7.  Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model.

Authors:  Anna Énzsöly; Katalin Markó; Tamás Tábi; Éva Szökő; Romána Zelkó; Miklós Tóth; J Mark Petrash; Péter Mátyus; János Németh
Journal:  J Neural Transm (Vienna)       Date:  2013-02-09       Impact factor: 3.575

8.  Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

Authors:  Patrick R Merz; Nina Röckel; Seda Ballikaya; Gerd U Auffarth; Ingo Schmack
Journal:  BMC Ophthalmol       Date:  2018-12-11       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.